STOCK TITAN
  1. Home
  2. News
  3. AKTX

Akari Therapeutics Plc - AKTX STOCK NEWS

Welcome to our dedicated news page for Akari Therapeutics Plc (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akari Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akari Therapeutics Plc's position in the market.

News
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
Rhea-AI Summary
Akari Therapeutics, Plc (AKTX) will present new pre-clinical data on investigational PAS-nomacopan at ARVO 2024. The drug's effect on electroretinography testing will be discussed, focusing on potential treatment for geographic atrophy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
News
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
Rhea-AI Summary
Akari Therapeutics, Plc (AKTX) reports financial results for 2023 and highlights progress in Phase 3 and pre-clinical development programs. CEO expresses optimism about merger and growth prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.03%
Tags
earnings
-
News
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
Rhea-AI Summary
Akari Therapeutics and Peak Bio Inc. Announce Merger Agreement to Create a Combined Entity with a Robust Pipeline and Strategic Focus on Advanced Therapies for Autoimmune and Inflammatory Diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
acquisition
News
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) closed a private placement financing with existing investors, resulting in gross proceeds of approximately $2 million. The company issued 947,868 unregistered American Depository Shares at a purchase price of $2.11 per ADS. Paulson Investment Company, LLC acted as the exclusive placement agent for this financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
none
-
News
Akari Therapeutics to Present at Biotech Showcase 2024
Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) will present a company overview at Biotech Showcase in San Francisco, CA on January 8, 2024. President and CEO Rachelle Jacques will lead the presentation, focusing on advanced therapies for autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.84%
Tags
conferences
-
News
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) announced the appointment of Samir R. Patel, M.D. to the Akari Board of Directors. Dr. Patel, an experienced life sciences entrepreneur, brings broad life sciences experience and a track record of successful startup companies. He currently serves as founder and principal of PranaBio Investments, LLC, and is a consultant to GE Global Research. Dr. Patel has over 20 years of experience in life sciences and has held multiple roles in Medical Affairs with Centocor, Inc. He received his medical degree from the Medical College of Ohio and completed his internal medicine internship and residency, as well as a rheumatology fellowship, at University of New Mexico School of Medicine Affiliated Hospitals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.49%
Tags
management
News
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
Rhea-AI Summary
Akari Therapeutics, Plc (Nasdaq: AKTX) announces positive pre-clinical results for long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The company plans to submit an IND in 2024 for Phase 1 testing to evaluate safety and pharmacokinetics/pharmacodynamics (PK/PD). The development includes an advanced high yielding manufacturing process, supporting the program's progression into clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
clinical trial
-
News
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
Rhea-AI Summary
Akari Therapeutics, Plc announced that Chief Scientific Officer Miles Nunn will present a poster on the development of PASylated®-Nomacopan for the treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference. The poster will be presented on November 15, 2023, at 3:00 pm ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences clinical trial
-
News
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
Rhea-AI Summary
Akari Therapeutics announced financial results for the first half of 2023. The company's priority pipeline programs are on track, with enrollment in Phase 3 clinical trials expected to begin soon. Akari received orphan drug designation from the European Commission, adding to existing FDA designations. The company also strengthened its capabilities with new appointments. Akari's lead asset, nomacopan, is progressing well in development for various indications. The company is also advancing its long-acting PAS-nomacopan program for geographic atrophy. Akari's financial results show a net loss of approximately $3.0 million for the first half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
earnings
News
Akari Therapeutics to Present at Emerging Growth Conference
Rhea-AI Summary
Akari Therapeutics to participate in Emerging Growth Conference on October 4 and 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.77%
Tags
conferences acquisition
Stock AKTX logo
Akari Therapeutics Plc

Nasdaq:AKTX

AKTX Rankings

N/A Ranked by Market Cap
#4941 Ranked by Stock Gains
N/A Ranked by Dividends

AKTX Stock Data

9.16M
9.56B
17.91%
1.61%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About AKTX

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.